Two of the things we work on turn out to be the same conversation more often than most people realize. Obstructive sleep apnea and obesity travel together, and the research connecting them to GLP-1 medications got noticeably more interesting over the past month.
Here is what landed, in plain language, including the parts that don’t support a tidy headline.
The July study
On July 13, researchers published an analysis in Laryngoscope Investigative Otolaryngology looking at 133,050 adults with obstructive sleep apnea drawn from the TriNetX Clinical Trials Network database. They compared cardiovascular outcomes in patients prescribed a GLP-1 receptor agonist against patients who were not.
Among people with OSA who were not using CPAP, a GLP-1 prescription was associated with lower rates of several serious cardiac events. Reported as rate ratios, where 1.0 would mean no difference:
- Heart failure — 0.500
- Cardiac arrest — 0.300
- Ventricular arrhythmias — 0.385
- Myocardial infarction — 0.650
- Atrial fibrillation or flutter — 0.833
- Coronary intervention or bypass — 0.333
Those are large-looking numbers, and they’re the reason the study got picked up widely.
What the study does not establish
This is an observational database analysis, not a randomized trial. That distinction does real work here, and skipping past it is how a reasonable finding turns into a bad marketing claim.
Association is not causation. People who get prescribed a GLP-1 differ from people who don’t in ways a database can’t fully account for — engagement with the healthcare system, access to insurance, other conditions, and the simple fact that a clinician judged them appropriate for the medication in the first place. Some of the benefit in these numbers may belong to those differences rather than the drug.
It is not a reason to stop CPAP. The comparison that generated the striking numbers was within the group not prescribed CPAP. Read carefully, the finding is about people who currently have no airway treatment at all — not evidence that a medication should replace one that’s working for you. Decisions about starting, changing, or stopping CPAP belong with the licensed clinician managing your care.
It says nothing about compounded medications. The prescription data here covers manufactured branded products. We’ll come back to this.
The apnea evidence itself
Separately from cardiac outcomes, there’s a growing body of work on whether GLP-1 based therapy changes sleep apnea severity directly, measured by the apnea-hypopnea index — the count of breathing interruptions per hour that defines how severe someone’s OSA is.
The SURMOUNT-OSA program is the most rigorous piece of that picture: two 52-week randomized, placebo-controlled phase 3 trials in adults with moderate-to-severe OSA and obesity, testing tirzepatide at maximum tolerated dose. Participants on tirzepatide saw a significant reduction in AHI compared with placebo. Post-hoc analyses have looked at how many participants moved down a severity category.
Work presented at the 2026 ATS International Conference added a wrinkle worth knowing: response isn’t uniform. Researchers identified a “strong responder” subgroup — skewing younger, with milder obesity and particular physiological traits — who improved roughly twice as much as everyone else. Which means the average result in a trial is a poor prediction of any individual’s result, including yours.
The part that applies to compounded medications
Every trial described above studied a branded, manufactured product made by its manufacturer under an approved application.
Compounded semaglutide and tirzepatide — the medications NoBsRx provides provider-guided access to — are prepared by state-licensed 503A pharmacies for an individual patient. They are not FDA-approved products, and they have not been through SURMOUNT-OSA or any equivalent trial. Nobody has run a randomized controlled trial of compounded tirzepatide for sleep apnea.
We’re not going to blur that line. If a telehealth company tells you the sleep apnea research is evidence for the compounded product they’re selling you, they are stretching a study past what it covers. The honest version is narrower: the active ingredient class has trial evidence in OSA, the specific compounded preparation does not, and whether any of it applies to you is a clinical question for a licensed provider who knows your history.
Why we care about this at all
There’s a practical reason this research matters beyond the science.
Sleep apnea is badly underdiagnosed. Roughly three in four adults with obesity have it, and most never find out. That means a large number of people currently taking a GLP-1 for weight also have untreated OSA, don’t know it, and have no baseline measurement of it.
That’s the gap our sleep program exists to close. A 3–5 night at-home study on an FDA-cleared ring, read by a board-certified sleep clinician, produces an actual AHI number for you instead of an average from a trial population. If treatment is clinically appropriate, it gets coordinated. If your data doesn’t support a diagnosis, you find that out too — and you’re better off knowing.
You can’t track whether anything improved if you never measured where you started.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program and it is not a claim that any medication will treat sleep apnea. Compounded medications are not FDA-approved. Treatment is never guaranteed — eligibility, diagnosis, and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any treatment, including CPAP, based on an article. If you think you may have sleep apnea, talk to a licensed clinician.